Key result
Single therapy with a beta1-blocker for POTS or an alpha-agonist for orthostatic intolerance relieved orthostatic symptoms in 60% of the patients.
Why the study?
Does targeted pharmacotherapy (atenolol for POTS, alpha-agonist for OI) improve orthostatic symptoms in dizzy patients with orthostatic dysregulation?
Observational (n=23)
Does targeted pharmacotherapy (atenolol for POTS, alpha-agonist for OI) improve orthostatic symptoms in dizzy patients with orthostatic dysregulation?
Targeted pharmacotherapy based on autonomic profiling may relieve symptoms in a majority of patients with POTS or chronic orthostatic intolerance.
May support targeted pharmacotherapy in orthostatic dysregulation; leaves open confirmation by randomized trials.
Patients with orthostatic dysregulation (OD)-associated disease may show autonomic disorders more frequently as compared with patients with other types of dizziness. However, the pathological mechanisms of OD remain unclear. We examined the cardiovascular autonomic function in dizzy patients with postural orthostatic tachycardia syndrome (POTS) or chronic orthostatic intolerance (OI) in order to evaluate the contribution of the autonomic disorders to the occurrence of dizziness. Heart rate variability analysis during the Schellong test showed that patients with POTS have hypo-parasympathetic function and relative hyper-sympathetic function, and that some patients with OI also have hypo-parasympathetic function. In our clinic, single therapy with a β1-blocker (Atenolol) for patients with POTS or single therapy with an a- agonist for patients with OI relieved orthostatic symptoms in 60% of the patients with POTS and OI. Further clinical studies on OD-associated disease to evaluate methods for accurate diagnosis and appropriate combined physical and pharmacotherapy may improve the outcomes in patients with OD-associated disease.
No takes yet. Share an insight, caveat, or question.
Mitsuhiro Aoki (2008) conducted an observational in Orthostatic dysregulation (POTS and Orthostatic Intolerance) (n=23). Beta1-blocker (Atenolol) or alpha-agonist was evaluated on Relief of orthostatic symptoms. Single therapy with a beta1-blocker for POTS or an alpha-agonist for orthostatic intolerance relieved orthostatic symptoms in 60% of the patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: